Evidence map›Paper›PMID 38281616›Full record

ArticleCellular signalling2024

GCN5L1-mediated acetylation prevents Rictor degradation in cardiac cells after hypoxic stress.

Paramesha Bugga, Janet R Manning, Bellina A S Mushala, Michael W Stoner, John Sembrat, Iain Scott

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Paramesha BuggaVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, United States of America.
Janet R ManningVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, United States of America.
Bellina A S MushalaVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, United States of America.
Michael W StonerVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, United States of America.
John SembratDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America.
Iain ScottVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, United States of America; Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, United States of America. Electronic address: iain.scott@pitt.edu.
University of Pittsburgh · US

Funding

Novel strategies to resolve metabolic defects in the diabetic heartR01HL147861 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2020 to 2024
$2.4M
Fatty acid oxidation in female cardioprotectionR01HL156874 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2022 to 2025
$2.2M
Targeting the hepatic adropin signaling pathway in obesityF31DK134089 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MUSHALA, BELLINA · 2023 to 2023
$43k
NHLBI NIH HHS R01 HL147861NHLBI NIH HHS R01 HL156874NIDDK NIH HHS F31 DK134089
6 · The paper itself

Abstract

Cardiomyocyte apoptosis and cardiac fibrosis are the leading causes of mortality in patients with ischemic heart disease. As such, these processes represent potential therapeutic targets to treat heart failure resulting from ischemic insult. We previously demonstrated that the mitochondrial acetyltransferase protein GCN5L1 regulates cardiomyocyte cytoprotective signaling in ischemia-reperfusion injury in vivo and hypoxia-reoxygenation injury in vitro. The current study investigated the mechanism underlying GCN5L1-mediated regulation of the Akt/mTORC2 cardioprotective signaling pathway. Rictor protein levels in cardiac tissues from human ischemic heart disease patients were significantly decreased relative to non-ischemic controls. Rictor protein levels were similarly decreased in cardiac AC16 cells following hypoxic stress, while mRNA levels remained unchanged. The reduction in Rictor protein levels after hypoxia was enhanced by the knockdown of GCN5L1, and was blocked by GCN5L1 overexpression. These findings correlated with changes in Rictor lysine acetylation, which were mediated by GCN5L1 acetyltransferase activity. Rictor degradation was regulated by proteasomal activity, which was antagonized by increased Rictor acetylation. Finally, we found that GCN5L1 knockdown restricted cytoprotective Akt signaling, in conjunction with decreased mTOR abundance and activity. In summary, these studies suggest that GCN5L1 promotes cardioprotective Akt/mTORC2 signaling by maintaining Rictor protein levels through enhanced lysine acetylation.

Indexed as

Myocardial IschemiaProto-Oncogene Proteins c-aktAcetylationAcetyltransferasesHumansHypoxiaLysineMechanistic Target of Rapamycin Complex 2Mitochondrial ProteinsMyocytes, CardiacNerve Tissue ProteinsRapamycin-Insensitive Companion of mTOR ProteinTranscription FactorsAcetyltransferasesBLOC1S1 protein, humanLysineMechanistic Target of Rapamycin Complex 2Mitochondrial ProteinsNerve Tissue ProteinsProto-Oncogene Proteins c-aktRapamycin-Insensitive Companion of mTOR ProteinTranscription FactorsAktGCN5L1HypoxiaIschemiamTORC2Proteasomal degradationRictor

Identifiers

PMID38281616
PMCPMC10922666
OpenAlexW4391247753

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.